Skip to main content
. 2010 Oct 20;2(10):691–708. doi: 10.18632/aging.100210

Figure 8. Inhibition of PARG activity reduces both DNA-PKcs and tankyrase 1 protein levels.

Figure 8.

(A) Treatment with the PARG inhibitor ADP-HPD (10 hr) prevents removal of pADPr from PARP modified proteins and resulted in reduction of DNA-PKcs levels relative to the DMSO treated control. The combination treatment of both ADP-HPD and XAV939 (10 hr) resulted in reduction of DNA-PKcs, similar to XAV939 treatment alone (Figure 7A). (B) PARG inhibition also decreased protein levels of tankyrase 1 compared to control. ADP-HPD/XAV939 combined treatment resulted in elevated tankyrase 1 levels, similar to XAV939 treatment alone (Figure 7B).